A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Preclinical work at the University of Michigan has demonstrated that inhibition of c-Met
with cabozantinib prevented the development of metastatic disease in an intra-cardiac
injection model in NOD/SCID mice. Additionally, the combination of cabozantinib and
gemcitabine demonstrated improved tumor control compared to either agent alone in a relevant
orthotopic implantation mouse model.
Combining gemcitabine with the c-Met inhibitor cabozantinib in advanced pancreatic cancer is
a novel strategy that takes advantage of an established cytotoxic agent with one that
targets a pathway known to be important for the growth, dissemination, and resistance of
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose
The MTD is defined at the highest dose level at which ≤25% of patients experience a dose-limiting toxicity (DLT).
Mark Zalupski, MD
University of Michigan Cancer Center
United States: Food and Drug Administration
|University of Michigan Comprehensive Cancer Center||Ann Arbor, Michigan 48109-0752|